With MindMed's latest financing, total cash reserves now stand at CAD$50.1 million.
Markets are tumbling. Where do you want to be positioned AFTER the selloff is over? Psychedelic stocks.
MAPS' recent economic study revealed huge cost savings from MDMA-assisted therapy to treat PTSD. But that could be just the beginning of the savings.
As the new rally in psychedelic stocks progresses, these four companies are currently setting the pace.
An enormous Crisis. Huge treatment markets. Massive disruption potential. Welcome to the psychedelic drug industry.
With its new digital therapeutics platform, Mind Cure is positioning itself as an emerging leader in the psychedelic drug industry.